


Lewy-Dx: the first blood test to diagnose dementia with Lewy bodies



OVERVIEW

A new dementia case occurs every three seconds, with many cases being misdiagnosed as Alzheimer's (AD) instead of dementia with Lewy bodies (DLB). This causes healthcare professionals to give patients the wrong treatment, leading to severe side effects. To address this, the Lewy-Dx test uses a simple blood sample to measure specific miRNAs and accurately distinguish DLB from AD, improving diagnosis and treatment.

PROJECT

Sector: Oncology

R&D direction: Genomics and Transcriptomics of Synucleinopathies with the objective of molecular characterization and identification of biomolecular markers

Stage of development: TRL4-5

Scientific leader: Dr. Katrin Beyer

PRODUCT

Indications: Neurology, Neurodegenerative diseases

Mechanism of action: Detection and quantification of specific miRNA in blood platelets

Market Size: €8B in 2023

IP PROTECTION

Patent Filed

OPPORTUNITY

Licenseout

Spin-off incorporation

Co-development

NEED

Dementia with DLB is the second leading cause of dementia after Alzheimer's disease but, due to its clinical similarities, only 30% of cases are correctly diagnosed. This leads to inappropriate treatments which can cause severe secondary effects in the patient.

SOLUTION

Our solution is based on the quantification of a specific set of molecules, known as miRNAs, which are present at varying levels in the blood platelets of DLB patients. By using a blood sample and standard laboratory techniques, combined with dedicated software, our diagnostic test can accurately differentiate DLB from AD, significantly improving diagnosis and enhancing patient management.

KEY ADVANTAGES

- Accurate diagnosis: distinguishes between DLB and AD, reducing misdiagnosis by up to 70%.
- Improved treatment: enables appropriate therapies for DLB patients, avoiding harmful side effects.
- Early detection: allows for timely diagnosis, improving patient management and outcomes.

CONTACT US!

innovation@igtp.cat

Innovation & Business Development Unit

